Q3 2022 Results slide image

Q3 2022 Results

Company overview Financial review 2022 priorities Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials Cardiovascular Immunology Neuroscience Oncology Neuroscience References Abbreviations Other 59 Investor Relations | Q3 2022 Results NOVARTIS | Reimagining Medicine
View entire presentation